Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT07630155
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Renal Pelvis and Ureter Urothelial Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Analgesic Agent — DRUG
    Given PO
  • Electronic Health Record Review — OTHER
    Ancillary studies
  • Lidocaine Topical — DRUG
    Given intraurethrally
  • Medical Device Usage and Evaluation — DEVICE
    Undergo ureteroscopy using 6.3 Fr single use digital ureteroscope
  • Survey Administration — OTHER
    Ancillary studies
  • Ureteroscopy — PROCEDURE
    Undergo ureteroscopy

Study Details

This clinical trial tests how well office based ureteroscopy utilizing a single use digital, flexible ureteroscope works for the assessment of upper tract urothelial carcinoma. Ureteroscopy is a procedure in which a thin camera called a ureteroscope is used to assess patients with a known or suspected diagnosis of upper tract urothelial carcinoma. Ureteroscopy is traditionally performed in an operating room under general anesthesia. In this study, patients undergo ureteroscopy in the doctor's office using an ultra-thin ureteroscope, which is the narrowest instrument of its kind. Because of its small size, researchers believe this procedure can be completed in the office with minimal discomfort and high patient satisfaction, which may eliminate the risks of general anesthesia and reduce delays to diagnosis. Office based ureteroscopy utilizing a single use digital, flexible ureteroscope may be effective for the assessment of upper tract urothelial carcinoma.

Key Dates

Start date
Jul 18, 2026
Status verified
Jun 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Diagnostic (in office ureteroscopy)
    Patients receive lidocaine jelly intraurethrally for local anesthesia. Patients then undergo ureteroscopy using the 6.3 Fr single use digital ureteroscope. Per standard of care practice, patients receive pain medication PO on an as needed basis prior to and immediately after the procedure.

Primary Outcome Measure

Success rate [ Time Frame: On day of procedure ]

Central Contacts

Locations (1)

FacilityCityStateZIP
University of Michigan Rogel Cancer CenterAnn ArborMichigan48109

Find similar trials in Ann Arbor, MI

By research site
University of Michigan Rogel Cancer Center· Ann Arbor, MI

Related Studies